Author:
Martin Samantha L.,Kuo Hui-Chien,Boggess Kim,Dugoff Lorraine,Sibai Baha,Lawrence Kirsten,Hughes Brenna L.,Bell Joseph,Aagaard Kjersti,Gibson Kelly S.,Haas David M.,Plante Lauren,Metz Torri D.,Casey Brian M.,Esplin Sean,Longo Sherri,Hoffman Matthew,Saade George R.,Foroutan Janelle,Tuuli Methodius G.,Owens Michelle Y.,Simhan Hyagriv N.,Frey Heather A.,Rosen Todd,Palatnik Anna,Baker Susan,August Phyllis,Reddy Uma M.,Kinzler Wendy,Su Emily J.,Krishna Iris,Nguyen Nicki,Norton Mary E.,Skupski Daniel,El-Sayed Yasser Y.,Ogunyemi Dotun,Galis Zorina S.,Ambalavanan Namasivayam,Oparil Suzanne,Librizzi Ronald,Pereira Leonardo,Magann Everett F.,Habli Mounira,Williams Shauna,Mari Giancarlo,Pridjian Gabriella,McKenna David S.,Parrish Marc,Chang Eugene,Osmundson Sarah,Quinones JoAnne,Werner Erika,Szychowski Jeff M.,Tita Alan T. N.,
Abstract
OBJECTIVE:
To compare differences in postpartum blood pressure (BP) control (BP below 140/90 mm Hg) for participants with hypertension randomized to receive antihypertensive treatment compared with no treatment during pregnancy.
METHODS:
This study was a planned secondary analysis of a multicenter, open-label, randomized controlled trial (The CHAP [Chronic Hypertension and Pregnancy] trial). Pregnant participants with mild chronic hypertension (BP below 160/105 mm Hg) were randomized into two groups: active (antihypertensive treatment) or control (no treatment unless severe hypertension, BP 160/105 mm Hg or higher). Study outcomes were BP control below 140/90 mm Hg (primary) and medication nonadherence based on a composite score threshold (secondary) at the 6-week postpartum follow-up visit. Participants without follow-up BP measurements were excluded from analysis of the BP control outcome. Participants without health care professional–prescribed antihypertensives at delivery were excluded from the analysis of the adherence outcome. Multivariable logistic regression was used to adjust for potential confounders.
RESULTS:
Of 2,408 participants, 1,684 (864 active, 820 control) were included in the analysis. A greater percentage of participants in the active group achieved BP control (56.7% vs 51.5%; adjusted odds ratio [aOR] 1.22, 95% CI, 1.00–1.48) than in the control group. Postpartum antihypertensive prescription was higher in the active group (81.7% vs 58.4%, P<.001), and nonadherence did not differ significantly between groups (aOR 0.81, 95% CI, 0.64–1.03).
CONCLUSION:
Antihypertensive treatment of mild chronic hypertension during pregnancy was associated with better BP control below 140/90 mm Hg in the immediate postpartum period.
Funder
National Heart, Lung, and Blood Institute
National Center for Advancing Translational Sciences
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference29 articles.
1. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Whelton;Hypertension,2018
2. Chronic hypertension in pregnancy;Battarbee;Am J Obstet Gynecol,2020
3. Management of mild chronic hypertension during pregnancy: a review;Ferrer;Obstet Gynecol,2000
4. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis;Lancet,2021
5. Patient adherence and medical treatment outcomes: a meta-analysis;DiMatteo;Med Care,2002